FDA Agrees to Reduced 4WARD Trial Sample Size
Analysis based on 7 articles · First reported Sep 08, 2026 · Last updated Sep 08, 2026
The FDA's agreement to reduce the sample size lowers the cost and time required for the 4WARD trial, potentially accelerating the path to regulatory submission and commercialization of mavorixafor for chronic neutropenia. This positive regulatory development is likely to boost investor confidence in X4 Pharmaceuticals, as reflected in the modest pre-market share price increase.
X4 Pharmaceuticals announced a positive outcome from its Type C meeting with the United States — Food and Drug Administration regarding the global 4WARD Phase 3 clinical trial for mavorixafor in chronic neutropenia. The FDA agreed to reduce the trial's sample size from 176 to 126 participants, maintaining adequate statistical power for the co-primary endpoints of reduction in annualized infection rate and positive absolute neutrophil count response. The FDA also indicated that the proposed safety database would be acceptable to support a potential supplemental new drug application. X4 expects to complete enrollment by year-end 2026 and report topline data in the first half of 2028. The company's shares rose about 2% in pre-market trading following the announcement.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard